0000-0001-7364-9327 About
RNAi and Oral cancer drug resistance.
Employment
Employment history is unavailable.
Education
-
National Institute of Technology Rourkela PhD in RNAi and Cancer drug resistance2021 - Present
Projects & Funding
Projects & funding information is unavailable.
Publications (9)
- Integrated omics and virtual screening predict Tabularin as a dual inhibitor of the prognostic microRNAs mir-19a and mir-32 in colorectal cancer Save
- microRNA-203a-3p sensitizes cisplatin through disruption of RAN-dependent RRM2 nuclear localization and mitochondrial stress readouts Save
- KLF5-mediated transcriptional activation of miR-203a inhibits EMT and increases cisplatin sensitivity by targeting SNAI2 in Tongue cancer Save
- Cisplatin disrupts OCT1-DNMT1-piRNA epigenetic regulatory axis to suppress GAB2-mediated aggressiveness in OSCC Save
- Silent Guardians Gone Rogue: The Role of PIWI and piRNA in Malignant Transformation Save
- A piRNA chemosensitizes doxorubicin in tongue squamous cell carcinoma by targeting FDFT1 and inhibiting the EIF3H/HIF1α/CYPOR axis Save
- miR-185-5p rewires cisplatin resistance by restoring miR- 203a-3p expression via downregulation of SOX9 Save
- miR-203a-A multifaceted regulator modulating cancer hallmarks and therapy response. Save
- Emerging roles of PIWI-interacting RNAs (piRNAs) and PIWI proteins in head and neck cancer and their potential clinical implications. Save